Company Overview and News
Reata Pharmaceuticals (NASDAQ:RETA) begins Phase 1 clinical trial to evaluate the safety and pharmacokinetics of RTA 1701. RTA 1701 is one of a series of highly selective and orally bioavailable allosteric inhibitors of RORyt. The series has the potential to treat a wide range of autoimmune and inflammatory disorders. RORγt is the master transcription factor controlling the differentiation of naïve CD4+ precursor cells into Th17 cells.
MBRX CYDY ARGX HBIO AKAO RETA STAA ATOS MDT
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"[email protected],"!O8FH-/#PO3&EN96%R:7IE9" [email protected],S,X M,[email protected] Q,2]%(#(X,[email protected],B]4(#,S-3([email protected]@6R [email protected],30Y73X^#65N M9&]B:@[email protected](" @(" @(" @(" @(" @(" @#0HQ-B P(&]B:@T\/"]$96-O9&50 M87)M7!E+UA2968O5ULQ(#(@,5T^/G-T('$UZT,3(P,,T!*&!B9_C/[email protected]\08 "/[email protected][email protected] M#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @ M(" @#0HQ.2 P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X,R],96YG [email protected]@-S O4R T.
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"[email protected],"!O8FH-/#PO3&EN96%R:7IE9" [email protected],S,V M-S(O3R Q,2]%(#(X,C7!E+UA2968O5ULQ(#(@,5T^/G-T('$U_4,3(P,,T!*&!B9_C/[email protected]\08 "/[email protected][email protected] M#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @ M(" @#0HQ.2 P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X,R],96YG [email protected]@-S O4R T.#X^
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT
Good afternoon and welcome to the Atossa Genetics conference call to discuss the company's business. All participants will be in listen-only mode. [Operator Instructions] Please note we will not have a Q&A session on this call. Also, this presentation is being recorded.
SEATTLE, May 15, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has received a second positive interim safety review on its Phase 1 study of topical Endoxifen in men, which is being developed to address gynecomastia (or male breast enlargement), a common condition in patients being treated for prostate cancer.
2017-11-07 - Asif
Atossa Genetics is a clinical-stage pharmaceutical company focused on developing novel, proprietary therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company currently have three programs underway: two using its proprietary endoxifen (oral and topical formulations) and the other using its patented microcatheter technology. The company's proprietary oral and topical forms of endoxifen are the subject of a comprehensive Phase 1 clinical study in healthy women in Australia. The company's patented microcatheter technology is in a Phase 2 clinical study that is also currently enrolling patients. Approximately one in eight women will be diagnosed with breast cancer during their lifetime. Every two minutes an American woman is diagnosed with breast cancer; 40,000 die each year. Tamoxifen has been widely used for over 30 years to both treat and prevent breast cancer. Additional research has shown that it is the metabolites of tamoxifen, o...
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
Silicon Investor Message Boards
This table lists all message boards related to ATOS / Atossa Genetics Inc on message board site Silicon Investor.
|STLW: Stratos Lightwave, Inc.||Stratos Lightwave, Inc.|
|STRATOS GLOBAL (T.SGB)||TOWV Stratosphere|
|Stratosphere,will be bought?|
as of ET